View Older Stories View More Recent Stories

May 24, 2022 07:00AM Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
May 23, 2022 04:05PM Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 08:03AM Aldeyra Therapeutics (ALDX) Reports Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap
May 18, 2022 08:00AM Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Ove
May 5, 2022 07:00AM Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
May 4, 2022 08:30AM Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
Apr 28, 2022 04:05PM Aldeyra Therapeutics Announces Chief Financial Officer Transition
Apr 27, 2022 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
Apr 21, 2022 08:00AM Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Apr 5, 2022 08:00AM Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
Mar 29, 2022 08:00AM Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
Mar 22, 2022 08:00AM Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
Mar 17, 2022 07:00AM Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
Mar 14, 2022 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
Mar 10, 2022 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights
Mar 8, 2022 08:00AM Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa
Feb 10, 2022 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference
Feb 1, 2022 08:00AM Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
Jan 11, 2022 08:08AM Aldeyra Therapeutics (ALDX) Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra
Jan 11, 2022 08:00AM Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
Jan 6, 2022 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
Jan 4, 2022 08:00AM Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Dec 20, 2021 04:05PM Aldeyra Therapeutics (ALDX) Phase 3 TRANQUILITY Trial in Dry Eye Disease Does Not Meet Primary Endpoint
Dec 20, 2021 04:05PM Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
Nov 9, 2021 04:05PM Aldeyra Therapeutics to Participate in Upcoming Conferences
Nov 9, 2021 08:00AM Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Nov 2, 2021 08:03AM Aldeyra Therapeutics (ALDX) Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Nov 2, 2021 08:00AM Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Oct 28, 2021 07:00AM Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
Oct 21, 2021 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
Sep 9, 2021 08:00AM Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Sep 2, 2021 08:00AM Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Aug 5, 2021 07:00AM Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
Aug 4, 2021 08:00AM Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
Aug 3, 2021 08:00AM Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Jul 29, 2021 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
Jul 20, 2021 08:01AM Aldeyra Therapeutics (ALDX) Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
Jul 20, 2021 08:00AM Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
Jul 1, 2021 08:00AM Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
May 27, 2021 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
May 6, 2021 07:00AM Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
Apr 29, 2021 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
Apr 27, 2021 07:03AM Aldeyra Therapeutics (ALDX) Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
Apr 27, 2021 07:00AM Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
Apr 26, 2021 04:05PM Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
Mar 11, 2021 07:00AM Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
Mar 10, 2021 08:00AM Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021
Mar 4, 2021 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights
Mar 2, 2021 08:00AM Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Feb 18, 2021 08:00AM Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
View More Recent Stories View Older Stories